

China Consumer

Expecting encouraging data from the 5.1 holiday this year

- Overall foot traffic. We expect encouraging 5.1 travel data. According to various sources and news we monitor, air passenger during the holiday is likely to surpass 9mn persons, tracking approximately 110% of the level we saw in 2019. Splitting between domestic and overseas travellers, the former will likely grow by approximately 25%, while, for the latter, the recovery could track up to 30-40% of that in 2019. By destination, air ticket booking to Hainan grew by 1.5x, and Hainan represented 93% of the travel destination of domestic trips.
- **Dutyfree.** Relative to 2022, when the 5.1 holidays was filled with short-haul travelers or even campers, search rate for domestic air ticket this year has surged by 3x approaching the holiday. This is despite when tourist to Hainan slightly retreated in April, subsequent to the strong 1Q, and it is still tracking approximately 10% above to that of 2019. While Hainan remains a popular tourist destination, we are optimistic about the dutyfree data to be reported this holiday with growth rate likely surpassing that of last year. For instance, dutyfree sales reported by the 10 dutyfree operators in 2022 was RMB645mn (+39%) with over 64,000 shoppers (+13%).
- Cosmetics. 5.1 is not traditionally a strong sales season for cosmetics. According to Moojing, March cosmetic sales grew by 10% YoY, in line with that of total social retail sales. While momentum seemed to have cooled down since Double 11 last year, on a positive note, along with more frequent social gatherings, the use-up of cosmetics on-hand should set stage for a bigger spending wallet for the upcoming 6.18.
- Baijiu/ beer. We do not see the holiday to stimulate any gifting demand. However, outdoor activities should fuel higher on-trade consumption, particularly for beer when outdoor BBQ has been popular recently. March and April sales have not been strong historically, and inventory has piled up a bit but not to an alarming level. Our recent channel check with distributors indicated that wholesales pricing for sealed Feitian Moutai per bottle has recovered to about RMB2,950 (from the low of RMB2,900 in March).
- Stock-for-action. Proya (603605CH, Buy) is our top buy within cosmetics, followed by Botanee (300957CH, Buy). We like CDF's exposure (601888CH, Buy) to China's reopening. Within F&B, we like CR Beer (291HK, Buy), Tsingtao (168HK, Buy) and Moutai (600519CH, Buy).

			Mkt Cap	TP	Upside/	P/E (x)		P/B (x)	ROE (%)
Name	Ticker	Rating	(US\$ mn)	(LC)	Downside	FY23E	FY24E	FY23E	FY23E
Food and beverage									
CR Beer	291 HK	BUY	25,334	74.8	22.0	34.8	30.2	5.8	16.6
Tsingtao	168 HK	BUY	18,868	86.0	3.2	26.3	23.2	3.7	14.0
BudAPAC	1876 HK	HLD	37,707	27.2	21.7	29.8	27.7	3.3	11.0
Moutai	600519 CH	BUY	320,150	2,440.0	38.8	31.3	26.9	8.7	28.9
Dutyfree/ cosmetics									
CTGDF	601888 CH	BUY	48,260	256.0	58.4	31.7	24.6	7.9	25.1
Botanee	300957 CH	BUY	7,124	157.0	35.3	35.8	28.6	7.5	20.9
Proya	603605 CH	BUY	6,799	184.0	11.2	47.7	37.3	11.3	23.6
Jahwa	600315 CH	BUY	2,825	39.2	36.6	25.8	22.0	2.5	9.6

Source: Company data, BBG, CMBIGM estimates

MARKET PERFORM (Maintain)

China Consumer

Joseph Wong (852) 3900 0838 josephwong@cmbi.com.hk

Related Reports

- Proya Cosmetics (603605 CH) 1Q in line; 2023 guidance maintained – 21 Apr 2023
- Kweichow Moutai (600519 CH)

 1Q came in slightly higher than
 we expected 17 Apr 2023
- CR Beer (291 HK) An in-line 2H22; our top pick among China F&B names – 27 Mar 2023
- CTGDF (601888 CH) Still the crown jewel among reopening plays – 14 Feb 2023
- CR Beer (291 HK) Another positive year for 2023; our preferred pick for China's reopening – 22 Jan 2023
- 6. CTGDF (601888 CH) At the forefront of China's reopening 20 Dec 2022
- CTGDF (601888 CH) A weak 3Q on Sanya's lockdown; resilient online sales made up the gap but unavoidably diluted GPM - 4 Nov 2022



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

CMBIGM Ratings

BUY
Stock with potential return of over 15% over next 12 months
SELL
Stock with potential return of +15% to -10% over next 12 months
SELL
Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.